“…Consistently, grade (G) ≥ 3 anemia according to Common Terminology Criteria for Adverse Events (CTCAE), which presented in about 20% of subjects, was less frequent with veliparib (7% in the VELIA trial) and more common with niraparib (31% and 25% in the PRIMA and NOVA trial, respectively) [ 14 , 33 , 34 ]. Decrease of hemoglobin level was also common in early phase trials evaluating the ATR inhibitors elimusertib and bezosertib [ 35 , 36 ], CHK1 inhibitor prexasertib [ 23 , 37 , 38 , 39 ] and WEE1 inhibitor adavosertib [ 40 , 41 , 42 ]. However—with the exception of elimusertib, which determined an 81% rate of G3/4 anemia—this AE was mainly low grade [ 23 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 ].…”